Healthcare
Siegfried Holding AG(SGFEF)
Live Price
Offline$100.00
+0.00% today
1Y Change
-12.55%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $3.45B
- Revenue Growth
- +2.6%
- EPS Growth
- +3.8%
- Dividend Yield
- 0.5%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Siegfried Holding AG (SGFEF) is a Healthcare stock with a market cap of $3.45B and listed on OTC. The stock last traded around $100.00 and down 12.5% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +2.6%, EPS growth of +3.8%, a dividend yield of 0.5%. What stands out right now is revenue +2.6%, EPS +3.8%, free cash flow +182.7% with operating margin 15.7% and ROIC 9.2%. The dividend is present but secondary, with a yield around 0.5%. Valuation is more restrained than many high-expectation growth names at P/E 20.4 and price/sales 2.6. Stock Foundry combines SGFEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.6% vs +7.6% peer median
Operating Margin
Below sector median
+15.7% vs +19.4% peer median
P/E
Below sector median
20.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Feb 20, 2026 with an EPS surprise of +1.8% and a revenue surprise of -1.9%.
The operating story is still moving forward
Revenue is running at +2.6% and EPS at +3.8%, with operating margin around 15.7%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 21, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 20, 2026 | +1.8% | +0.0% | +0.0% | -4.4% |
2025 Jun 30, 2025 | -2.6% | +0.0% | +0.0% | +0.0% |
2025 Feb 18, 2025 | +895.6% | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SGFEF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SGFEF Max Drawdown
-12.55%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SGFEF and SPY.
Company Overview
Siegfried Holding AG
Other OTC
Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
- Leadership
- Marcel Imwinkelried
- IPO Date
- Jul 25, 2014
- Employees
- 3.9k
- Street Address
- Untere Bruehlstrasse 4
- Mailing
- Zofingen, 4800
- Region
- Zofingen, CH
- Reporting Currency
- USD
- Investor Line
- 41 62 746 1111
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 20.4
- EV/EBITDA
- 12.9
- Price/Sales
- 2.6
- Price/Book
- 3.1
Growth
- Revenue
- +2.6%
- EPS
- +3.8%
- Free Cash Flow
- +182.7%
Profitability
- Gross Margin
- 26.7%
- Operating Margin
- 15.7%
- Net Margin
- 12.7%
- ROE
- 15.7%
- ROIC
- 9.2%
Balance Sheet
- Debt/Equity
- 0.51
- Current Ratio
- 2.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.